Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study
Tulane University · NCT04814420
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 60
- US sites recruiting
- 3
- Study start
- July 12, 2021
- Record last updated
- June 15, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The investigators hypothesize that Obstructive Sleep Apnea (OSA) is an independent risk factor for atrial fibrosis development. The investigators aim to prove the presence of atrial fibrosis on Delayed Enhancement Magnetic Resonance Imaging (DE-MRI) in OSA patients without atrial fibrillation (AF).
Being studied: Delayed enhancement magnetic resonance imaging (DE-MRI)
Conditions: Atrial Fibrillation; Obstructive Sleep Apnea
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Group A: 10 patients 18-75-year-old With mild OSA (5\<AHI\<15), confirmed by polysomnography. No previous AF diagnosis on the medical chart
Group B: 10 patients 18-75-year-old With moderate OSA (15\<AHI\<30), confirmed by polysomnography. No previous AF diagnosis on the medical chart
Group C: 10 patients 18-75-year-old With severe OSA (AHI>30), confirmed by polysomnography. No previous AF diagnosis on the medical chart
Group D (mild OSA+ AF): 10 patients 18-75-year-old With mild OSA (5\<AHI\<15), confirmed by polysomnography. Previous AF diagnosis
- In this group, patients with AF and OSA who already have done MRI might be included.
Group E (severe OSA +AF): 10 patients 18-75-year-old With severe OSA (AHI>30), confirmed by polysomnography. Previous AF diagnosis
*In this group, patients with AF and OSA who already have done MRI might be included.
Group F (Control): 10 Patients 18-75-year-old No previous OSA and/or AF Diagnosis on the medical chart
Exclusion Criteria
- History of chronic heart failure (LVEF \< 50%), AF, myocardial infarction, valvular disease.
- Prior cardiac or chest surgery.
- Other advanced pulmonary disease (severe Chronic Obstructive Pulmonary Disease (COPD) or asthma, pulmonary hypertension) or central sleep apnea.
- Contraindications to DE-MRI (e.g. allergy to gadolinium, pacemakers, defibrillators (ICD's), other devices/implants contraindicated for MRI, glomerular filtration rate \<30 ml/min, etc.).
- Pregnancy.
- Inability to give informed consent.
Recruiting US locations
East Jefferson General Hospital
New Orleans, LA 70006
Site contact: Christian Massad, MD · 504-988-3072 · cmassad@tulane.edu
University Medical Center
New Orleans, LA 70112
Site contact: Christian Massad, MD · 504-988-3072 · cmassad@tulane.edu
Tulane Doctors - Speciality Care - Napoleon
New Orleans, LA 70115
Site contact: Christian Massad, MD · 504-988-3072 · cmassad@tulane.edu
Study contacts (from the official record)
- Christian Massad, MD · 504-988-3072 · cmassad@tulane.edu
- Kunal Sameer, MD, MHA · 504-988-3072 · ksameer@tulane.edu
Similar studies in Louisiana
All sleep studies in Louisiana →- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Shreveport, LA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Axsome Therapeutics, Inc.
- Location
- Kenner, LA + 37 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
- Location
- New Orleans, LA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Cardiovascular Risk and Circadian Misalignment in Short Sleepers - Role of Extended Eating Period
Pennington Biomedical Research Center
- Location
- Baton Rouge, LA
- Eligibility basics
- Ages 18–45